1 |
Kundim, B. A., Y. Hou, Y. Sakagami. R. Fudou, S. Yamanaka, and M. Ojima (2004), Novel antifungal poltene amides from Cystobacter fuscus, Tetrahedron 60, 10217-10221
DOI
ScienceOn
|
2 |
Cowden, C. J., and I. Paterson (1997), Cancer drugs better than taxol? Nature 387, 238-239
DOI
ScienceOn
|
3 |
Choi, S. U., N. Y. Kim, E. J. Choi, K H. Kim, and C. O. Lee (1996), Establishment of doxorubicin-resistant subline derived from HCT15 human colorectaI cancer cells, Arch. Pharm. Res. 19, 342-347
DOI
ScienceOn
|
4 |
Skehan, P., R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J. Warren, H. Bokesch, S. Kenny, and M. R. Boyd (1990), New colorimetric cytotoxicity assay for anticancer drug screening, J. Nat. Cancer Inst. 82, 1107-1112
DOI
PUBMED
|
5 |
Jansen, R., H. Irschik, H. Reichenbach, and G. Hofle (1997), Chivosazoles A-F: Novel antifungal and cytotoxic macrolides from Sorangium cellulosum (Myxobacteria), Liebigs Ann. 1997, 1725-1732
DOI
|
6 |
Ahn, J. W., and C. O. Lee (2004), Isolation of antibiotics effective to multidrug-resistant cancer cells from Sorangium cellulosum (Myxobacteria), Kor. J. Microbiol. Biotechnol. 32(1), 47-51
|
7 |
Halt, J. G., N. R. Krieg, P. H. A. Sneath, J. T. StaIeg, and S. T. Williams (1994), Bergey's Manual of Determinative Bacteriology 9th ed., William and WiIkans, Baltimore, USA
|
8 |
Lum, B. L., M. P. Gosland, S. Kaubisch, and B. I. Sikic (1993), Molecular targets in oncology: implications of the multidrug resistance gene, Pharmacotherapy 13, 88-109
|
9 |
Abu, J. W., S. H. Woo, C. O. Lee, K. Y. Cho, and B. S. Kim (1999), KR025, a new cytotoxic compound from Myxococcus fulvus, J. Nat. Prod 62(1), 495-496
DOI
ScienceOn
|
10 |
Reichenbach, H. and M. Dworkin (1992), The Myxobacteria, p. 3416-3487. In A. Balowsm, H. G. Truper, and M. Dworkin (eds.), The Prokaryotes (2nd ed.), Springer Verlag, New York
|
11 |
Reichenbach, H., K. Gerth, H. Irschik, B. Kunze, and G. Hofle (1988), Myxobacteria: a source of new antibiotics, TIBTECH. 6, 115-121
DOI
ScienceOn
|
12 |
Sasse, F., H. Steinmetz, J. Heil, G. Hofle, and H. Reichenbach (2000), Tubulysins, new cytostatic peptides from myxobacteria acting on microtubuli, J. Antibiotics 53(9), 879-885
DOI
ScienceOn
|
13 |
David, W. (2000), Biology and global distribution of myxobacteria in soils, FEMS Microbiol. Reviews 20, 400-420
|
14 |
IIwahashi, T., E. Okochi, K. Ono, L. Sugawara, T. Tsuruo, and S. Mori (1991), Establishment of multidrug resistant human colorectaI carcinoma HCT15 cell line and their properties, Anticancer Res. 11, 1309-1312
|
15 |
Reichenbach, H., and G. Hofle (1993), Biologically active secondary metabolites from myxobacteria, Biotech. Adv. 11, 219-277
DOI
ScienceOn
|
16 |
Ueda, K., G. Cardarelli, M. M. Gottesman, and I. Pastan (1987), Expression of a full length cDNA for the human MDR-1 gene confers resistance to colchicine, doxorubicin, and vinblastin, Proc. Natl. Acad Sci. USA. 84, 3004-3008
|
17 |
Wessjohann, L. (1997), Epothilones: Promising natural products with taxol-like activity, Angew. Chem. Int. Ed. 36(7), 715-718
DOI
ScienceOn
|
18 |
Miyashiro, S., S. yamanaka, S. Takayama, and H. Shibai (1998), Novel macrocyclic antibiotics: Megovalicins A-G, J. Antibiotics 41(4), 433-438
|
19 |
Ahn, J. W. (2002), Cytotoxic polyene antibiotics from Myxococcus stipitatus JW111, J. Korean Soc. Agric. Chem. Biotechnol. 45(2), 114-118
|
20 |
Kunze, B., R. Jansen, F. Sasse, G. Hofle, and H. Reichenbach (1998), Apicularen A and B, new cytostatic macrolides from Chondrornyces species (Myxobacteria), J. Antibiotics 51(12), 1075-1080
DOI
ScienceOn
|
21 |
Perez, R. P., T. C. Hamilton, R. F. Ozoles, and R. C. Young (1993), Mechanisms and modulation of resistance to chemotherapy in ovarian cancer, Cancer 71, 1571-1580
DOI
ScienceOn
|
22 |
Irschik, H., R. Jansen, K. Gerth, G. Hofle, and H. Reichenbach (1995), Chivosazol A, a new inhibitor of eukaryotic organisms isolated from myxobacteria, J. Antibiotics 48(9), 962-966
DOI
|